Entrectinib can induce sinus bradycardia as a rare but serious cardiac adverse effect in patients with metastatic non-small cell lung cancer.
Does entrectinib cause sinus bradycardia in patients with metastatic non-small cell lung cancer?
A patient with metastatic non-small cell lung cancer (NSCLC)
Entrectinib
Sinus bradycardiasafety
Entrectinib, a multikinase inhibitor used for ROS1 fusion-positive NSCLC, is associated with rare but serious cardiac adverse effects such as sinus bradycardia.
Targeted therapies like tyrosine kinase inhibitors have significantly improved outcomes in non–small cell lung cancer. Entrectinib, a multikinase inhibitor, showed efficacy in ROS1 fusion-positive NSCLC, including intracranial metastases. Although generally well tolerated, rare but serious cardiac adverse effects have been reported.
Building similarity graph...
Analyzing shared references across papers
Loading...
Azita H. Talasaz
Anne J. Goldberg
Catherine A. Shu
JACC Case Reports
Columbia University
Columbia University Irving Medical Center
NewYork–Presbyterian Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Talasaz et al. (Sun,) reported a other. Entrectinib can induce sinus bradycardia as a rare but serious cardiac adverse effect in patients with metastatic non-small cell lung cancer.
www.synapsesocial.com/papers/69ba431a4e9516ffd37a3f45 — DOI: https://doi.org/10.1016/j.jaccas.2026.107369